Literature DB >> 7213001

Anal cloacogenic carcinoma: classification and clinical behavior.

A I Serota, M Weil, R A Williams, J S Wollman, S E Wilson.   

Abstract

A retrospective study of 35 patients with anal cloacogenic carcinomas showed that the histological characteristics of the tumors were correlated with their biological behavior. The basaloid squamous type of cloacogenic carcinoma was more common in women (3.6:1) and had a more favorable course in both men and women, with a mean survival of 5.0 years. Glandular variants of these tumors, with an adenocystic or mucoepidermoid pattern, occurred predominantly in men and had a more aggressive course, manifested by early metastases to inguinal and mesenteric lymph nodes, liver, and lung, with mean survival limited to 2.5 years. Nine of the 11 patients who survived longer than five years had the basaloid squamous histological pattern and were treated by abdominoperineal resection or pelvic exenteration; five of these patients also received postoperative therapy with radiation. The overall actual five-year survival for patients with anal cloacogenic carcinoma was 41% in this study. The histological pattern of anal cloacogenic carcinoma provides useful prognostic information to the clinician.

Entities:  

Mesh:

Year:  1981        PMID: 7213001     DOI: 10.1001/archsurg.1981.01380160066013

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Anal cancer - a review.

Authors:  Sajad Ahmad Salati; Azzam Al Kadi
Journal:  Int J Health Sci (Qassim)       Date:  2012-06

2.  Anal epidermoid carcinoma: a population-based clinico-pathological study of 164 patients.

Authors:  S Goldman; B Glimelius; L Påhlman; E Ståhle; E Wilander
Journal:  Int J Colorectal Dis       Date:  1988-06       Impact factor: 2.571

3.  Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study.

Authors:  Zihao Wan; Zhihao Huang; Vikash Vikash; Kelash Rai; Sindhu Vikash; Liaobin Chen; Jingfeng Li
Journal:  Oncotarget       Date:  2017-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.